Plasma thrombin neutralization assay: pharmacokinetic applications

Area of Science:

• Pharmacology
• Biochemistry
• Hematology

Background:

• Unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) are vital for preventing and treating deep vein thrombosis (DVT).
• The antithrombotic mechanism of LMWHs, particularly their anti-IIa activity, has been challenging to elucidate due to the reported short half-life of this activity.
• Standard anti-IIa assays may underestimate LMWH activity due to limitations in artificial assay conditions.

Purpose of the Study:

• To develop and validate a more sensitive assay for measuring anti-IIa activity.
• To re-evaluate the pharmacokinetic profile of LMWHs using the enhanced assay.
• To better understand the role of anti-IIa activity in the therapeutic effects of LMWHs.

Main Methods:

• Development of a novel, sensitive anti-IIa assay based on thrombin-antithrombin (TAT) complex formation.
• In vitro validation of the assay's sensitivity using UFH and LMWHs.
• Ex vivo pharmacokinetic studies in humans administering UFH or LMWHs (Fraxiparine, Enoxaparine) subcutaneously, with anti-IIa activity measured by the new assay (PTNA).

Main Results:

• The developed assay (PTNA) demonstrated higher sensitivity, detecting anti-IIa activity at concentrations as low as 0.01 anti-Xa IU/mL for UFH and 0.05 anti-Xa IU/mL for LMWHs.
• Ex vivo analysis revealed the time course of plasma anti-IIa activity for very low doses of UFH and LMWHs.
• Pharmacokinetic evaluation of Fraxiparine and Enoxaparine in healthy volunteers provided new insights into their anti-IIa activity profiles.

Conclusions:

• The novel assay provides a more accurate assessment of anti-IIa activity compared to standard methods.
• The findings suggest that the anti-IIa activity of LMWHs may have a longer duration than previously estimated.
• This improved understanding of LMWH pharmacokinetics can refine their clinical application in thrombosis management.